SecBot SecBot
SECBOTREPLAY Home › Report › SMMT

SMMT · Summit Therapeutics presented updated overall survival (OS) data from…

Summit Therapeutics Inc. · 8-K filed Sep 15, 2026 at 08:44 ET

At the news

BULLISHIMPACT 7/10

8-K filed Sep 15, 2026 at 08:44 ET

Summit Therapeutics presented updated overall survival (OS) data from the global Phase III HARMONi trial (ivonescimab + chemo in EGFR-mutated NSCLC) and detailed OS results from the China-based HARMONi-2 trial (ivonescimab monotherapy vs. pembrolizumab) at WCLC 2026. The HARMONi data showed a consistent OS benefit with a hazard ratio of 0.76 (nominal p=0.0151) in the global ITT population, with western patients now showing a similar HR of 0.76, reinforcing the drug's profile ahead of the November 14, 2026 PDUFA date. HARMONi-2 showed a statistically significant OS benefit for ivonescimab over pembrolizumab (HR 0.73, p=0.009), further strengthening the clinical case for the asset across multiple lung cancer settings.

  • Updated HARMONi OS HR of 0.76 (95% CI: 0.61-0.95; nominal p=0.0151) in global ITT population at June 2026 data cut-off.
  • Western patient subgroup OS HR improved to 0.76 (95% CI: 0.52-1.10) with longer follow-up (median 23.2 months), matching the global trend.
  • HARMONi-2 showed ivonescimab monotherapy beat pembrolizumab on OS with HR 0.73 (95% CI: 0.57-0.95; p=0.009), including a 7.6-month median OS advantage (30.8 vs 22.6 months).
  • PDUFA goal date for the ivonescimab BLA in the U.S. is November 14, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access